BridgeMD
New treatment option for Bronchopulmonary Dysplasia
Official title Ventilator Pressure and Optimization of Compliance and Hemodynamics
ClinicalTrials.gov ID: NCT06512935
What this study is testing
- What it's testing
- In preterm infants \< 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with electrical impedance tomography (EIT) to optimize ventilator settings in preterm infants.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 7 to 30
You may be able to join if
- Preterm infants with recovering respiratory distress syndrome (RDS) who were born at a gestational age \< 34 weeks and are receiving respiratory...
- Post-natal age \> 7 days and less than 1 month (outside golden week protocol)
- Gestational age ≥ 21 weeks and ≤ 34 week
- Infants with written informed consent obtained from legal guardian
You likely can't join if
- Blood culture-positive sepsis
- Congenital anomalies affecting respiration
- Cyanotic or ductal-dependent congenital heart disease
- Newborns who are considered too unstable for study enrolment per neonatology attending
- Newborns on pressors or steroids for maintaining cardiac output
- Non-invasive ventilation or newborn with significant BPD (bronchopulmonary dysplasia) with pulmonary hypertension (HTN)
See the full eligibility criteria
- Preterm infants with recovering respiratory distress syndrome (RDS) who were born at a gestational age \< 34 weeks and are receiving respiratory support via conventional mechanical ventilation or on HFJV.
- Post-natal age \> 7 days and less than 1 month (outside golden week protocol)
- Gestational age ≥ 21 weeks and ≤ 34 week
- Infants with written informed consent obtained from legal guardian
- Blood culture-positive sepsis
- Congenital anomalies affecting respiration
- Cyanotic or ductal-dependent congenital heart disease
- Newborns who are considered too unstable for study enrolment per neonatology attending
- Newborns on pressors or steroids for maintaining cardiac output
- Non-invasive ventilation or newborn with significant BPD (bronchopulmonary dysplasia) with pulmonary hypertension (HTN)
- Open skin wounds or abrasions on the chest wall.
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 7 days to 30 days. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.